Genasense(R) Shown Active Using Intermittent Dosing In Melanoma Preclinical Studies

... Genta Incorporated (Nasdaq: GNTA) announced the presentation of new data related to the Company's research program in solid tumors. In preclinical models, high- dose intermittent treatment with Genasense was both efficacious and associated with increased uptake of the drug within tumors. The use of Genasense plus Abraxane(R) (paclitaxel protein-bound particles; Abraxis Oncology, Inc. [click link for full article] ...